How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,030 results for

E/M Examination Criteria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

10961. Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

). This study will also examine the interactions between different levels of behavioral and drug treatments. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Methylphenidate 0.15 mg/kg Behavioral: Low-Intensity BMOD Drug: Methylphenidate 0.3 mg/kg Drug: Placebo Drug: Methylphenidate 0.6 mg/kg Behavioral: High Intensity BMOD Not Applicable Detailed Description: Participants attend a summer treatment program each Monday-Friday for 9 weeks. They participate (...) : No Treatment No Medication, No Behavior Modification (BMOD) Drug: Placebo Active Comparator: Low Dose Medication Only 0.15 mg/kg methylphenidate (MPH), No BMOD Drug: Methylphenidate 0.15 mg/kg 0.15 m/kg/dose immediate-release methylphenidate Active Comparator: Medium Dose Medication Only 0.3 mg/kg MPH, No BMOD Drug: Methylphenidate 0.3 mg/kg 0.3 mg/kg/dose immediate-release methylphenidate Active Comparator: Higher Dose Medication Only 0.6 mg/kg MPH, No BMOD Drug: Methylphenidate 0.6 mg/kg 0.3 mg/kg/dose

2002 Clinical Trials

10962. Effects of Yohimbine and Naltrexone on Sexual Function

) medical or neurological illnesses likely to affect physiology or anatomy, c) a history of drug (including BZDs) or alcohol abuse within 1 year or a lifetime history of alcohol or drug dependence (DSM IV criteria), d) smokers, e) diagnosis of a sexual disorder, f) criminal history. Persons must exhibit no or only moderate alcohol use. Persons with current or previous regular use ( more than 4 weeks) of BZDs and excessive use of alcohol (more than 8 ounces/day) in the past or presence are ineligible (...) and naltrexone are drugs that may influence these neurotransmitter systems. This study will use different doses of yohimbine and fixed doses of naltrexone to determine their effectiveness in treating ED. Participants in this study will be screened with a medical history, physical examination, blood and urine tests, and an electrocardiogram (ECG). The study will consist of three outpatient visists. Condition or disease Intervention/treatment Erectile Dysfunction Drug: Naltrexone HCL/ Yohimbine HCL Detailed

2002 Clinical Trials

10963. A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas

a diary documenting the dose, site of administration, and any side effects. The diary will be reviewed at each National Cancer Institute (NCI) visit. Patients will return to NCI before cycles 2 and 3. If there are no significant side effects, patients may then return to NCI before every other cycle, indefinitely (i.e., before cycles 5, 7, 9, etc.). Patients will undergo the following tests and procedures: Physical examination, including neurologic exam, monthly Complete blood count, differential (...) )) in pediatric patients. Eligibility: Age: Patients must be less than or equal to 21 years of age. Histological Diagnosis: Histologic confirmation is not required for this study. Patients must have a diffuse pontine glioma as diagnosed by MRI criteria below. Radiologic Appearance: Patients must have a diffuse intrinsic tumor with the epicenter presumed to be in the pons. The T-2 weighted sequence must reveal a diffuse signal abnormality involving at least 50 percent of the pons. Prior Therapy: The patient

2002 Clinical Trials

10964. Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction

) Study Details Study Description Go to Brief Summary: This is a phase I study of the experimental anticancer drug oxaliplatin. It is designed to establish the maximum dose of the drug that can be given safely to patients with cancer who have impaired liver function and to determine the drug's side effects. It will also examine how liver function affects the drug's elimination from the body. The liver plays an important role in the elimination of many anticancer drugs, and patients with impaired liver (...) function should not take certain drugs or should take them in reduced doses. Patients 18 years of age and older with cancer that has metastasized (spread from the original tumor site) and for whom standard treatment is not available or is no longer effective may be eligible for this study. Candidates will be screened with various tests and procedures that may include physical examination, computerized tomography (CT) or magnetic resonance imaging (MRI) scans, chest X-rays, and blood and urine tests

2000 Clinical Trials

10965. Charleston Heart Study

and Locations Go to No Contacts or Locations Provided More Information Go to Publications: Keil JE, Gazes PC, LoadHolt CB, Gross AJ, Sutherland S, Tyroler HA, Knowes M, Rust PF: Coronary Heart Disease and Its Predictors in Charleston, South Carolina Women. In: Coronary Heart Disease in Women. Eaker E et al (Eds). Haymarket Doyma, Inc., New York, N.Y., 1987 Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 1038 First Posted: May 26, 2000 Last Update Posted (...) Study Description Go to Brief Summary: To examine the role of isolated systolic hypertension and other predictors of all-cause and coronary heart disease mortality in elderly Blacks and whites of the Charleston Heart Study cohort of 1960 and to compare and pool those findings with the Evans County Heart Study findings in order to develop a logistic risk function for Blacks. Also, to identify predictors of physical functioning in older Blacks and whites and to prepare rosters of the off-spring

2000 Clinical Trials

10966. Minneapolis Children's Blood Pressure Study

Summary: To examine environmental and familial correlates of childhood blood pressure in order to predict elevated blood pressure in young adulthood. Also, to investigate the phenomena of tracking of blood pressure and obesity from childhood to young adulthood. Condition or disease Cardiovascular Diseases Heart Diseases Hypertension Obesity Detailed Description: BACKGROUND: Hypertension has been clearly identified as a major risk factor for coronary heart disease and stroke. Hypertension screening (...) to Layout table for study information Study Type : Observational Study Start Date : September 1977 Actual Study Completion Date : May 1997 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more

2000 Clinical Trials

10967. Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

Information Go to Publications: Stamler J, Stamler R, Liu K: High Blood Pressure: Role in Coronay Heart Disease, and Implications for Prevention and Control. In: Connor WE, Bristow DJ (Eds), Coronary Heart Disease - Prevention, Complications, and Treatment, Lippincott, Philadelphia, Pa, p 85-109, 1985 Stamler J, Farinaro E, Riccardi G, Stamler R, Mancini M: Does asymptomatic Hyperglycemia Always Have to be Treated? (Italian), J Ital Diabetol, 3:1-7, 1983 Kaplan NM, Stamler J (Eds): Prevention of Coronary (...) , Lung, and Blood Institute (NHLBI) Study Details Study Description Go to Brief Summary: To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. The four cohorts include the Chicago Heart Association Detection Project in Industry cohort, the Peoples Gas Company cohort first examined in 1958-1959, the Peoples Gas Company cohort first examined in 1959-1962, and the Western

2000 Clinical Trials

10968. Characterization Of Coronary Prone Pedigrees

obtained for total cholesterol, triglycerides, high density lipoprotein, apo B, apo A-1, and apo E. At clinical screening, information was obtained on relationships, dates and places of vital events for the index person, spouse, offspring, siblings, parents, aunts and uncles, grandparents, grand aunts and uncles, and great-grandparents. Information was obtained on blood pressure, height, weight, electrocardiograms, physician's history and physical examination. Information was also collected on tobacco (...) age-sex matched controls with at least three siblings and no coronary heart disease in siblings or parents served as controls. Study Design Go to Layout table for study information Study Type : Observational Study Start Date : July 1977 Study Completion Date : December 1991 Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family

2000 Clinical Trials

10969. Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

leukemic blasts translocations Secondary Outcome Measures : Correlation of minimal residual disease at completion of induction, beginning of continuation, and at completion of therapy with patient outcome Clinical prognostic features associated with outcome Correlation of biologic characteristics of leukemia cells at diagnosis with outcome Patterns of gene expression Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal (...) decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: up to 1 Year (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Newly diagnosed acute lymphoblastic leukemia (ALL) or acute undifferentiated

1999 Clinical Trials

10970. Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck

and neck node dissection (if appropriate). Specimens are collected from tumor tissue (necrosis-free, if possible), each wound quadrant, any neck disease with clinically negative nodes, and any neck disease with a single positive node for histologic and molecular analysis. Tissue and cells are examined for p53 mutation and DNA microsatellite repeat alterations. Patients undergo adjuvant radiotherapy and/or chemotherapy, as appropriate for clinical staging and histopathology, at the discretion (...) IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA Actual Study Start Date : January 17, 1996 Actual Primary Completion Date : October 18, 2002 Actual Study Completion Date : May 27, 2011 Resource links provided by the National Library of Medicine related topics: related topics: resources: Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

1999 Clinical Trials

10971. Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

[ Time Frame: 12 years ] 12 year survival comparison Secondary Outcome Measures : Freedom from progression [ Time Frame: 12 years ] Complete response rate [ Time Frame: 12 years ] Second disease progression rate [ Time Frame: 5 and 10 years ] Cause-specific survival rate [ Time Frame: 5 and 10 years ] treatment-related toxicity and Quality of Life. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk (...) with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 16 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Eligibility Criteria Histologically proven Hodgkin's Disease. A needle aspirate specimen

1999 Clinical Trials

10972. Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

of failure (local, regional or distant progression). Analysis occurs after patients have been potentially followed for 2.5 years. ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information (...) , Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically or cytologically proven newly diagnosed, stage IIIA (T1-3, N2) non-small cell lung cancer Eligible subtypes: Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Nonlobar and nondiffuse bronchoalveolar cell carcinoma Measurable or evaluable disease on chest x-ray and/or contrast CT

1999 Clinical Trials

10973. Down Syndrome

, 84132 United States, Washington Swedish Medical Center Seattle, Washington, United States, 98104-1377 Sponsors and Collaborators Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Investigators Layout table for investigator information Principal Investigator: Mary E. D'Alton, M. D. Columbia-Presbyterian Hospital Medical Center More Information Go to Publications: Malone FD, D'Alton, MD. Fetal nuchal translucency. Contemporary Obstetrics and Gyncology 1998; 43 (...) , and those who screen negative after the serum "quad" test, receive routine care with final pediatric outcome. Patients with an a priori risk for Down Syndrome may elect to have invasive fetal testing at 15 weeks after quad testing. For all fetuses with a NT measurement greater than 3 mm, and where karyotype is found to be normal after amniocentesis, will be followed with a repeat ultrasound examination at 18 to 20 weeks gestation, to evaluate fetal anatomy, particularly fetal cardiac structure. Final

2000 Clinical Trials

10974. Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

R, Samson P, Violari A, Palmer M, Kiser J, Fletcher C, Fenton T, Mofenson L, Graham B, Schnittman S, Horga M, Aldrovandi G, for the PACTG 1020A Study. Treatment responses to atazanavir-containing HAART in a drug-naïve pediatric population in South Africa. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2008. Rutstein R, Samson P, Aldrovandi G, Graham B, Schnittman S, Fletcher C, Kiser J, Smith E, Mofenson L, Fenton T, and the PACTG 1020A Study Team. Effect (...) and -Experienced HIV-Infected Infants, Children, and Adolescents Study Start Date : November 2000 Actual Primary Completion Date : October 2011 Actual Study Completion Date : September 2014 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Step I: Group 1 Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs. ATV Dose Tested: 310 mg/m^2, 620

2000 Clinical Trials

10975. Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

this approach for one of four cancers (breast, colon, lung, or prostate), using allele-sharing statistics to test the interaction of each locus with every other locus. Replicate positive results in a distinct set of sibling pairs with cancer. Examine, when loci contributing to risk are detected, the influence of this genetic background on clinical outcomes, such as survival. OUTLINE: Each patient-sibling pair completes a family history questionnaire about the incidence of cancer in the family. Blood samples (...) information Study Type : Observational Estimated Enrollment : 4000 participants Official Title: ECOG Laboratory Study: Mapping Interactive Cancer Susceptibility Loci Study Start Date : January 1998 Actual Primary Completion Date : December 2007 Resource links provided by the National Library of Medicine related topics: related topics: resources: Groups and Cohorts Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study

1999 Clinical Trials

10976. Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 120 Years (Adult, Older Adult) Sexes Eligible for Study: All (...) Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the head and neck All primary sites, including oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, and paranasal sinus Recurrent, unresectable, and/or metastatic disease At least 1 measurable lesion At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan Lesions accessible for biopsy Tumor specimen available for evaluation of epidermal growth factor

2002 Clinical Trials

10977. Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

for investigator information Study Chair: Amit M. Oza, MD Princess Margaret Hospital, Canada More Information Go to Publications of Results: Oza A, Elit L, Eisenhauer E, et al.: Phase II study of erlotinib (Tarceva, OSI 774) in women with recurrent or metastatic endometrial cancer -- NCIC IND.148. [Abstract] Clin Cancer Res 9 (Suppl): A-105, 6094s, 2003. Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: I148 CAN-NCIC-IND148 NCI-NCIC-148 CDR0000069169 ( Other (...) for study information Study Type : Interventional (Clinical Trial) Primary Purpose: Treatment Official Title: A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium Study Start Date : January 2002 Actual Primary Completion Date : April 2007 Actual Study Completion Date : April 2007 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go

2002 Clinical Trials

10978. Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

to Arm Intervention/treatment Experimental: Arm A - Standard BFM of Standard Duration (RER) Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper (...) , cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy. Drug: asparaginase Given IV Other Names: E. coli Elspar NSC-109229 Drug: cyclophosphamide Given IV Other Names: Cytoxan NSC-26271 Drug: cytarabine Given IV Other Names: Cytosine Arabinoside Ara-C Cytosar-U NSC-63878 Drug: daunorubicin hydrochloride Given IV Other Names: Daunomycin Hydrochloride Cerrubidine NSC-82151 Drug: dexamethasone Given IV Other Names: Decadron NSC

1999 Clinical Trials

10979. Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder

(including BZDs) or alcohol abuse within 1 year or a lifetime history of alcohol or drug dependence (DSM IV criteria), e) current pregnancy (as documented by pregnancy testing prior to scanning), f) current breast feeding, g) general MRI exclusion criteria, h) patients who are currently taking fluoxetine. Patients and controls must exhibit no or only moderate alcohol use. Subjects with current or previous regular (greater than 4 weeks) of BZDs and excessive use of alcohol (greater than 8 ounce/day (...) Sponsor: National Institute of Mental Health (NIMH) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: The purpose of this study is to examine how certain brain chemicals work in patients with Panic Disorder (PD) and Post-Traumatic Stress Disorder (PTSD) with and without major depressive disorder (MDD). Brain chemicals that regulate emotion, anxiety, sleep, stress hormones, and other body functions bind to serotonin (5-HT1A

2001 Clinical Trials

10980. Follow-up Visit of High Risk Infants

; medical equipment required; growth data; a detailed neurologic examination; Bayley Scales of Infant Development (mental, motor, infant behavior); Child Behavior Checklist. A sub-study will assess a reference group comprised of a limited number of healthy term infants born in Network centers to meet the following three aims: 1) to avoid potential ascertainment biases due to examiner expectations when only extremely preterm or other high-risk infants are assessed 2) in the absence of well-developed (...) norms for the Bayley Scales, to define thresholds for impairment based on data for a representative sample of healthy children born at term in our centers and concurrently assessed by the same examiners as for our high-risk infants; and 3) to help identify and address when "drift" occurs over time in conducting and scoring Bayley assessments. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 68000 participants Observational Model: Cohort Time

2001 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>